| Objective: To observe and evaluate the clinical efficacy of Zhichan decoction in the treatment of Parkinson’s disease(Wind-yang internal movement type),and its influence on serum levels of inflammatory factors interleukin-6(interleukin-6,IL-6)and tumor necrosis factor-α(tumor necrosis factor-α,TNF-α),in order to provide clinical basis for the treatment of Parkinson’s disease with traditional Chinese medicine.Methods: A randomized controlled trial design was adopted in this study.Sixty-six patients with Parkinson’s disease who met the inclusion criteria were selected from the Department of Neurology,Affiliated Hospital of Shandong University of Chinese Medicine from August 2021 to December2022,and divided into control group and treatment group according to random number method,with 33 patients in each group.Two groups of patients were enrolled to maintain the original underlying disease drug therapy.The control group was given conventional treatment with western medicine medoba(Dosiazid tablets),and the treatment group was additionally given self-designed Chinese prescription Zhichan decoction,the treatment cycle was 4 weeks.At the time of enrollment,the patients were rated by the modified Hoehn-Yahr rating scale,and the patients’ emotions,behaviors,daily living ability,exercise symptoms,TCM syndrome and so on were observed.Parkinson’s Disease Score Scale(UPDRS),modified Webster Symptom Score Scale and TCM syndrome total score were used to evaluate the patients before and after treatment,and the serum levels of IL-6 and TNF-α were observed before and after treatment.The obtained data were statistically analyzed by SPSS 26.0.Results: A total of 63 patients completed the study.There were 3 cases shedding during the treatment,31 cases in the final treatment group and32 cases in the control group.No adverse events occurred in the enrolled patients before and after treatment.1.Before treatment,general data such as gender,age,course of disease and H-Y grading of patients in the treatment group and the control group were analyzed,showing no statistical difference(P>0.05),indicating that the two groups were comparable.2.Comparison of scale scores: After treatment,UPDRS I,II,III scores,Webster symptom score and total TCM syndrome score of 2 groups were decreased compared with before treatment,and the treatment group was significantly decreased compared with control group,the difference was statistically significant(P<0.05).TCM single syndrome scores in 2 groups were lower than before treatment,the differences were statistically significant(P<0.05);The improvement of "limb tremor,head and chest tilt,gait panic,dizziness,tinnitus,facial red irritability,dry mouth bitter mouth,dry stool" in the two groups was significantly reduced compared with the control group,the difference was statistically significant(P<0.05);There was no statistical significance in the improvement of "indifferent expression,oral salivation,lack of fluency in speech,limb pain,limb numbness and red urine" between the two groups(P>0.05).3.Laboratory indicators: After treatment,serum IL-6 level in 2 groups was lower than before treatment,and the treatment group was significantly lower than control group,the difference was statistically significant(P<0.05).After treatment,the serum TNF-α level in 2 groups was lower than that before treatment,and the treatment group was significantly lower than the control group,with statistical significance(P<0.01).Conclusion: Compared with the western medicine metoba(Dosiazid tablets)in the treatment of Parkinson’s disease,Zhichan decoction combined with metoba(Dosiazid tablets)has more significant clinical efficacy in the treatment of Parkinson’s disease(Wind-yang internal movement type),and has more obvious advantages in improving clinical symptoms and reducing the levels of serum inflammatory factors(IL-6,TNF-α).It not only provides a new and efficient treatment for delaying the progress of Parkinson’s disease,but also provides a scientific basis for exploiting the advantages of traditional Chinese medicine... |